Historical aspects of botulinum toxin used clinically: part II: overcoming resistance Online publication date: Thu, 04-Aug-2016
by Andy Pickett
The Botulinum J. (TBJ), Vol. 3, No. 1, 2015
Abstract: After the extraordinary success of botulinum toxin serotype A in the 1980s to treat a wide range of spasmodic muscular conditions and movement disorders, a significant number of patients were found to stop responding to their treatments with time. When investigated, they were found to have become immune ('resistant') to the products. This second article in a series looks at the next botulinum toxin serotype used clinically after serotype A to overcome this resistance and how that choice was made.
Online publication date: Thu, 04-Aug-2016
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the The Botulinum J. (TBJ):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email email@example.com